| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From the Laboratory for Surgical Research, Children’s Hospital, Boston Massachusetts; the 2 Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; and the 3 Department of Pathology, Genentech, Inc., South San Francisco, California.
Abstract
PURPOSE. The expression of vascular endothelial growth factor (VEGF) and its high-affinity receptors VEGFR-1 and VEGFR-2 was investigated in normal eyes.
METHODS. Monkey and rat eyes were surgically removed in animals under deep anesthesia and immediately prepared for study. Ocular VEGF, VEGFR-1, and VEGFR-2 expression was studied using a combination of in situ hybridization, northern blot analysis, immunohistochemistry, immunoassay, and reverse transcription–polymerase chain reaction.
RESULTS. Steady state VEGF mRNA levels were detected in the normal vascularized ocular tissues of the monkey: the conjunctiva, iris, retina, and the choroid–retinal pigment epithelial complex. VEGF121 and VEGF165 were the major isoforms identified. VEGF protein was detected in the conjunctiva, retina, and the choroid–retinal pigment epithelial complex. Retinal VEGF mRNA localized to the ganglion, inner nuclear, and retinal pigment epithelial cell layers. VEGF protein localized to these same layers and to the cones of monkey retina. VEGFR-1 and VEGFR-2 mRNAs were detected in normal monkey iris, retina, and the choroid–retinal pigment epithelial complex. In both monkey and rat eyes, VEGFR-1 and VEGFR-2 mRNAs were localized to the inner nuclear layer of the retina.
CONCLUSIONS. VEGF, VEGFR-1, and VEGFR-2 are constitutively expressed in the vascularized tissues of normal eyes.
Vascular endothelial growth factor (VEGF) refers to a family of peptide growth factors that act primarily on blood vessels.1 The human VEGF gene produces up to five alternatively spliced mRNAs that code for proteins of 121, 145, 165, 189, and 206 amino acids.2 3 4 The mouse gene codes for proteins of 120, 164, and 188 amino acids.5 The different VEGF isoforms have varying affinities for heparin. The larger isoforms bind heparin avidly, whereas the smaller ones do not.6 As a result, the three smaller isoforms are detected in conditioned media and biologic fluids, and by comparison, the larger isoforms are found bound to heparin-like molecules in extracellular matrix and on cell membranes. Unlike acidic and basic fibroblast growth factor, all five VEGF isoforms contain a leader secretory peptide sequence for their efficient secretion.2 5
Two VEGF high-affinity receptor tyrosine kinases have been cloned and sequenced: VEGFR-1 (Flt-1; fms-like tyrosine kinase)7 and VEGFR-2 (KDR; kinase domain region or Flk-1 in the rodent).8 In addition, an alternatively spliced soluble variant of the membrane-bound VEGFR-1 mRNA has been described.9 VEGFR-1 and VEGFR-2 are structurally related to each other, containing seven extracellular immunoglobulin-like domains and a conserved intracellular tyrosine kinase domain.7 125I-VEGF autoradiography of rat tissues has demonstrated that VEGF binding is largely restricted to blood vessels and is associated with both fenestrated and nonfenestrated endothelium.10
VEGF, VEGFR-1, and VEGFR-2 are each essential for normal blood vessel development. Heterozygous deletion of the VEGF gene results in embryo death between days 8.5 and 9.5. The embryos are characterized by impaired angiogenesis and blood island formation.11 12 Homozygous deletion of VEGFR-2 leads to death of mice between embryonic days 8.5 and 9.5, with the embryos having no yolk–sac blood islands and endothelial cells.13 Homozygous VEGFR-1 deletion permits endothelial cell differentiation, but the vascular channels that form are grossly abnormal, and the animals die in utero.14
VEGF is a major mediator of retinal ischemia–associated ocular neovascularization.15 16 It is also the primary bioactive vascular endothelial cell mitogen synthesized and secreted by hypoxic retinal cells in vitro.17 When monkey retina is made ischemic, VEGF mRNA and protein levels increase in proportion to the amount of iris neovascularization that subsequently develops.18 The freely diffusible VEGF121 and VEGF165 are the major isoforms produced in ischemic retina.19 In humans with retinal ischemia, VEGF levels in the retina, vitreous, and aqueous temporally correlate with neovascularization of the retina, optic nerve, and iris.20 21 22 23
A causal role for VEGF in retinal ischemia–associated neovascularization has been demonstrated in two animal models. VEGF-neutralizing antibodies completely prevented iris neovascularization in a primate model,15 and soluble VEGF receptors suppressed retinal neovascularization in a mouse model.16 In gain-of-function experiments, exogenous VEGF has been shown to trigger iris and retinal neovascularization in monkeys,24 25 and retinal neovascularization develops in transgenic mice that overexpress VEGF in the retina.26
VEGF also appears to play an important role in other types of ocular neovascularization. Endogenous VEGF is required for corneal neovascularization in a rat model,27 and VEGF, VEGFR-1, and VEGFR-2 have been temporally and spatially associated with choroidal neovascularization in humans and monkeys.28 29
Several lines of evidence suggest that VEGF is also operative in the survival of newly grown vessels. The regression of experimental iris neovascularization is preceded by a decrease in aqueous VEGF levels in monkeys,18 and a similar decrease is observed after panretinal photocoagulation in humans.21 In the developing mouse eye, declining retinal VEGF levels have been correlated with the regression of newly formed vessels.30 Moreover, intravitreal injections of VEGF have been shown to rescue these new vessels from regression. It is not known whether VEGF is a survival factor for long-standing normal adult vessels, or whether it serves other nonvascular functions in the eye. To begin to investigate these questions, the expression and distribution of VEGF and its high-affinity receptors was studied in normal adult eyes.
Methods
Anesthesia and Enucleation
Animals were cared for in accordance with the ARVO Resolution for
the Use of Animals in Ophthalmic and Vision Research and guidelines
established by the Massachusetts Eye and Ear Infirmary, Children’s
Hospital, and the Genentech Animal Care Committees. General anesthesia
for monkeys was performed as previously described.15
Briefly, cynomolgus monkeys (Macacca fascicularis) and
Rhesus monkeys were anesthetized for all procedures with an
intramuscular injection of ketamine (20 mg/kg; Parke–Davis, Morris
Plains, NJ), acepromazine (0.15 mg/kg; Ayerst Laboratories, Rouses
Point, NY), and atropine sulfate (0.125 mg/kg; Gensia Laboratories,
Irvine CA). Male Sprague–Dawley rats (weight, 200–250 g) were
anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and
xylazine (10 mg/kg).
Seven monkey and four rat eyes were used. Different eyes were used for the polymerase chain reaction (PCR), northern blot analysis, immunohistochemistry, and in situ hybridization studies. Eyes were enucleated with animals under deep anesthesia. The globes were bisected at the equator, and the vitreous was removed. The bisected globes were then immediately placed in fixative as described later, or individual tissues were isolated using McPherson forceps and Vannas scissors. The retina, iris, lens, conjunctiva, and cornea were separately isolated, placed in a 50-ml conical plastic tube, and snap frozen in liquid nitrogen. Homogeneous samples of choroid and retinal pigment epithelium (RPE) could not be prepared rapidly, and they were therefore studied as a whole (choroid–RPE). The time from enucleation to isolation of all the tissues was less than 5 minutes. The animals were then killed with an overdose of sodium pentobarbital.
In Situ Hybridization
The in situ hybridization protocol and the preparation of
33P-labeled riboprobes have been previously
described.31
Briefly, species-specific PCR primers were
designed from available human and murine VEGF sequences to amplify a
0.9-kb (human) or 0.65-kb (rat) cDNA fragment. The antisense probes
hybridized to regions of VEGF mRNA coding sequence common to all known
splice variants of VEGF. The human VEGF probe was used on monkey
tissues, and the rat VEGF probe was used on rat tissues. Human VEGFR-1,
human VEGFR-2, and murine VEGFR-2 probes were designed from the
transmembrane region of each sequence. The 0.3-kb human VEGFR-2 probe
had less than 45% homology with VEGFR-1 and was used on monkey
tissues. The 0.5-kb human VEGFR-1 probe had more than 95% homology
among human, rat, and mouse and was used on both monkey and rat
tissues. The 1.2-kb murine VEGFR-2 probe was used on rat tissues and
had 51.1% homology with VEGFR-1. Appropriate sense and antisense
riboprobes were generated by in vitro transcription in the presence of
33P-uridine triphosphate. Adult monkey and
nonpigmented rat eyes were fixed in 4% paraformaldehyde, paraffin
embedded, and hybridized as previously described.31
Slides
were examined after 5 weeks’ exposure.
Immunohistochemistry
Rabbit polyclonal anti-human VEGF (1:100; Oncogene Science,
Cambridge MA) was used on formalin-fixed, paraffin-embedded Rhesus
monkey sections after microwave antigen retrieval with citrate buffer
(BioGenex, San Ramon CA). The antibodies recognize exons 1 to 5, which
are common to all VEGF isoforms. Nonimmune rabbit serum was used as a
negative control. The secondary antibody was detected with
streptavidin-alkaline phosphatase (Kirkegaard & Perry, Gaithersburg,
MD) and visualized with Fast Red TR/Naphthaol Phosphase (Research
Genetics, Huntsville, AL)
RNA Isolation and Northern Blot Analysis
Total RNA was isolated by the method of Chomczynski and
Sacchi32
after tissue homogenization (Polytron). RNA (15
µg) was electrophoresed through a 1% agarose-formaldehyde gel and
transferred to nylon filters (Gene Screen Plus; New England Nuclear,
Boston, MA). The filters were prehybridized in buffer containing 50%
deionized formamide, 5x SSPE, 5x Denhardt’s solution, 0.5% sodium
dodecyl sulfate (SDS), 10% dextran sulfate, and denatured salmon sperm
DNA (100 µg/ml) and hybridized at 42oC in fresh
buffer without salmon sperm DNA. The hybridization buffer contained
either a 520-bp NcoI/BglII fragment of the human
VEGF cDNA (gift of Herbert Weich), a 226-bp
EcoRI/BamHI fragment of human VEGFR-1, or
a 286-bp fragment of human VEGFR-2.33
The blots were
stripped and reprobed with a 400-bp fragment encompassing the 3'
untranslated region of the human ß-actin cDNA. The cDNA probes were
labeled with a random primed DNA labeling kit using
[
-32P] deoxy-CTP (Boehringer Mannheim, Indianapolis,
IN). Filters were washed in 2x–0.5x SSPE, 0.1% SDS, for varying
times and at increasing temperatures. The washes were titrated for
maximum signal-to-noise ratio. The hybridized and washed filters were
exposed to x-ray film (X-Omat AR; Eastman Kodak , Rochester, NY) with
an intensifying screen at -70oC for 12 to 72 hours.
Densitometry was performed on all blots and normalized to the
corresponding actin signal for each lane using a digital imaging system
(IS-1000 with ver. 1.97 software; Alpha Inotech, Torrence, CA).
Reverse Transcription–Polymerase Chain Reaction
Total RNA (1 µg) from the indicated tissues was reverse
transcribed with a commercially available kit (Advantage RT-for PCR;
Clontech, Palo Alto, CA) using the random hexamer primer according to
the manufacturer’s protocols. Duplicate reactions without MMLV reverse
transcriptase were included as negative control samples. A constant
fraction (1/20) of each reverse transcription reaction was amplified
with Taq DNA polymerase (Gibco, Gaithersburg, MD) using
oligonucleotide primers derived from highly conserved sequences in
intron 4 and the 3' untranslated region of the VEGF gene. The 5' primer
was GCGGAATTCATYATGCGGATCAAACCYCACCA, and the 3' primer was
TACGGATCCTCCGGACCCAAAGTGCTC. These primers can detect all VEGF
isoforms. Based on the sequence of human VEGF, the expected sizes of
the amplified products for each VEGF isoform were 593 bp (VEGF206), 542
bp (VEGF189), 470 bp (VEGF165), 410 bp (VEGF145), and 338 bp (VEGF121).
The latter four isoforms were observed after RT-PCR of RNA from monkey
lung (data not shown). The identity of the monkey VEGF products was
verified by cloning and sequencing.
Enzyme-Linked Immunosorbent Assay
Tissue lysates were prepared by washing the tissues with
phosphate-buffered saline (PBS) three times followed by addition of 1
ml/well lysis buffer (50 mM Tris, [pH 8.0], 2 M NaCl, 0.1% CHAPS,
1% NP40, 2 mM EDTA, 1 µg/ml aprotinin, 2 mM AEBSF, and 1 µg/ml
leupeptin; Sigma, St. Louis, MO). The lysate was cleared of debris by
centrifugation at 14,000 rpm for 30 minutes
(4oC), and the supernatant was assayed for VEGF.
Total protein was determined by the method of Bradford using a
commercial assay (Bio-Rad, Hercules, CA).34
Supernatant
VEGF levels were determined using an a sandwich enzyme-linked
immunosorbent assay (ELISA) according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN) and normalized to total
protein.
Results
Northern blot analysis for VEGF, VEGFR-1, and VEGFR-2 identified steady state levels for each transcript in normal cynomolgus monkey choroid–RPE complex, retina, and iris (Fig. 1) . VEGF was also detected in the conjunctiva; however, all three transcripts were absent in the lens. Insufficient RNA was isolated from the corneas for reliable analysis. RT-PCR identified VEGF121 and VEGF165 as the major VEGF transcripts in the tissues found to express VEGF (Fig. 2) . Faint PCR products were observed occasionally in these negative control lanes, presumably because of plasmid DNA contamination (Fig. 2) .
|
|
|
|
|
|
|
These analyses demonstrate that some normal ocular tissues constitutively express VEGF and its cognate receptors VEGFR-1 and VEGFR-2. The expression patterns for all three genes in normal monkey and rat eyes are generally consistent. The tissues studied were surgically isolated from living animals and immediately prepared for study. The rapid preparation of the tissues limited the possibility of artifactual gene expression and permitted analyses accurately reflecting the in vivo situation.
VEGF expression was largely limited to those tissues that are vascularized in the normal state: conjunctiva, iris, retina, and choroid–RPE. Little or no VEGF was detected in the avascular lens and cornea. The lens result may have been accentuated by lower RNA loading. The cornea result confirms our previously published finding that VEGF protein is virtually absent in normal cornea.27 We were also unable to detect message for VEGFR-1 or VEGFR-2 in lens. The in situ hybridization studies confirm the northern blot data and further demonstrate that VEGF mRNA expression is largely restricted to nonvascular cells. Further, little or no expression was seen in the circulating blood elements within vessels (data not shown). This is important because leukocytes possess the capacity to express VEGF.35 Finally, the ELISA and immunohistochemical data confirmed that the VEGF mRNA is translated into VEGF protein.
VEGF is an angiogenic factor. Because no active neovascularization occurs in normal eyes,36 37 it is possible that the VEGF observed in these studies is not bioactive. VEGF bioactivity was not tested, and it is conceivable that the VEGF that was detected was present in an inactive stored form bound to heparin. Basic fibroblast growth factor is stored in such a manner38 and is quickly released on injury.39 However, that VEGF121 and VEGF165 were the major isoforms identified in these studies argues against this possibility. VEGF121 and VEGF165 have lower heparin affinities and are less likely to bind to matrix and/or cell surfaces.
The constitutive expression of VEGF and its receptors in normal eyes is consistent with VEGF serving as a vascular survival factor. Several pieces of evidence support this hypothesis. Destruction of the RPE causes secondary degeneration of the subjacent choriocapillaris,40 a result consistent with the RPE’s producing a vascular survival factor. In these studies, VEGF mRNA and protein were shown to be present at relatively high levels in the RPE. Previous reports in pigmented human23 and mouse41 eyes have also shown an autoradiographic signal for VEGF in the RPE layer; however, this expression pattern may have been caused by the pigment granules in the RPE. Through the use of nonpigmented rat eyes in this study, the signal for VEGF in the RPE was confirmed. Dorey et al.42 have made a similar observation in the RPE of newborn albino rats. These data, together with the data showing constitutive VEGFR-1 and VEGFR-2 expression in the subjacent choriocapillaris, are consistent with VEGF acting as a choriocapillaris survival factor. The second piece of evidence comes from the rat model of retinopathy of prematurity (ROP) discussed earlier,30 in which VEGF withdrawal was associated with endothelial cell apoptosis and vessel regression. In that model, intravitreal injections of VEGF were able to rescue the new vessels, strongly implicating VEGF in the survival of newly grown vessels.
A third possible explanation for the constitutive expression of VEGF concerns its possible interaction with nonendothelial cells in the retina. Yang et al.43 recently demonstrated that VEGFR-2 is expressed in retinal progenitor cells of mouse retina. They also showed that the expression of VEGFR-2 persists throughout retinal neurogenesis and that retinal cell VEGFR-2 can be activated by VEGF in vitro. Consistent with these observations, our data show that VEGFR-1 and VEGFR-2 message is distributed throughout the inner nuclear layer in a pattern that appears to extend beyond the inner retinal vasculature. Other recently published data have also demonstrated that VEGF receptors are not exclusively expressed on endothelial cells in vivo. Brown et al.33 recently identified VEGFR-1 and VEGFR-2 receptors on uterine smooth muscle cells in vivo. When these cells were cultured in vitro, VEGFR-1 could be phosphorylated and was capable of inducing smooth muscle cell proliferation. Similarly, Soker et al.44 have shown that neuropilin-1 enhances binding of VEGF165 to VEGFR-2 on tumor cells. Thus, the biology of VEGF may be more complex than originally thought.
The expression pattern analyses shown here also suggest that oxygen may not be the sole physiological stimulus for VEGF expression in vivo. RPE cells express relatively high VEGF levels (Fig. 1) , yet they are exposed to some of the highest regional pO2 levels in the body.45 Stimuli known to exist within the eye (e.g., hypoglycemia, reactive oxygen intermediates, insulin-like growth factor-1, and advanced glycation end products) are each capable of increasing VEGF expression46 47 48 49 and may serve to modulate VEGF expression in the eye.
Because VEGF, VEGFR-1, and VEGFR-2 are constitutively expressed in the eye, it is possible that the pharmacologic inhibition of VEGF bioactivity may have adverse consequences. Methods that permit the inducible silencing of specific genes in adult ocular tissues should be used to investigate this theoretical possibility.50
Acknowledgements
The authors thank Kelly Hagler for the immunohistochemistry and Lucy Lu and Thu-Nhung Nguyen for the in situ hybridization. We also thank Larry Brown for the human VEGFR-1 and VEGFR-2 cDNAs used for the northern blotting.
Footnotes
Reprint requests: Anthony P. Adamis, MD, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114.
IK and AMR contributed equally to this work.
Supported by Howard Hughes Medical Institute (IK), Bausch and Lomb (SA), the Roberta W. Siegel Fund (APA), and Grant RO1 EY11627 from the National Eye Institute (APA).
Presented in part at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 1996.
Submitted for publication June 30, 1998; revised January 4, 1999; accepted February 16, 1999.
Proprietary interest category: E. (AMR)
References
This article has been cited by other articles:
|
|
 |
|
  H. Shimada, E. Akaza, M. Yuzawa, and M. Kawashima Concentration Gradient of Vascular Endothelial Growth Factor in the Vitreous of Eyes with Diabetic Macular Edema Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2953 - 2955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Roy, D. M. Hallman, Y.-P. Fu, M. Machado, and C. L. Hanis Assessment of 193 Candidate Genes for Retinopathy in African Americans With Type 1 Diabetes Arch Ophthalmol, May 1, 2009; 127(5): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Monson, J. R. Smith, M. L. Klein, and D. J. Wilson Clinicopathologic Correlation of Retinal Angiomatous Proliferation Arch Ophthalmol, December 1, 2008; 126(12): 1664 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Salom, M. Diaz-Llopis, S. Garcia-Delpech, P. Udaondo, M. Sancho-Tello, and F. J. Romero Aqueous Humor Levels of Vascular Endothelial Growth Factor in Retinitis Pigmentosa Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3499 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Dallabrida, N. S. Ismail, E. A. Pravda, E. M. Parodi, R. Dickie, E. M. Durand, J. Lai, F. Cassiola, R. A. Rogers, and M. A. Rupnick Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy FASEB J, August 1, 2008; 22(8): 3010 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P C. Issa, R P Finger, F G Holz, and H P N Scholl Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia Br. J. Ophthalmol., July 1, 2008; 92(7): 941 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Nishiguchi, M. Nakamura, H. Kaneko, S. Kachi, and H. Terasaki The Role of VEGF and VEGFR2/Flk1 in Proliferation of Retinal Progenitor Cells in Murine Retinal Degeneration Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4315 - 4320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nishijima, Y.-S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S. J. Samuelsson, G. S. Robinson, A. P. Adamis, et al. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury Am. J. Pathol., July 1, 2007; 171(1): 53 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R B Bhisitkul Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol., December 1, 2006; 90(12): 1542 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M S Spitzer, B Wallenfels-Thilo, A Sierra, E Yoeruek, S Peters, S Henke-Fahle, K U Bartz-Schmidt, P Szurman, and on behalf of the Tuebingen Bevacizumab Study Group Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells Br. J. Ophthalmol., October 1, 2006; 90(10): 1316 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lebherz, A. M. Maguire, A. Auricchio, W. Tang, T. S. Aleman, Z. Wei, R. Grant, A. V. Cideciyan, S. G. Jacobson, J. M. Wilson, et al. Nonhuman Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Overexpression of Vascular Endothelial Growth Factor Diabetes, April 1, 2005; 54(4): 1141 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. van Wijngaarden, D. J. Coster, and K. A. Williams Inhibitors of Ocular Neovascularization: Promises and Potential Problems JAMA, March 23, 2005; 293(12): 1509 - 1513. [Full Text] [PDF]
|
|
|
|
|
|
J. Gaudreault, D. Fei, J. Rusit, P. Suboc, and V. Shiu Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Renno, Y. Terada, M. J. Haddadin, N. A. Michaud, E. S. Gragoudas, and J. W. Miller Selective Photodynamic Therapy by Targeted Verteporfin Delivery to Experimental Choroidal Neovascularization Mediated by a Homing Peptide to Vascular Endothelial Growth Factor Receptor-2 Arch Ophthalmol, July 1, 2004; 122(7): 1002 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Bhutto, S. Y. Kim, D. S. McLeod, C. Merges, N. Fukai, B. R. Olsen, and G. A. Lutty Localization of Collagen XVIII and the Endostatin Portion of Collagen XVIII in Aged Human Control Eyes and Eyes with Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1544 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Zarbin Current Concepts in the Pathogenesis of Age-Related Macular Degeneration Arch Ophthalmol, April 1, 2004; 122(4): 598 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Frank Diabetic Retinopathy N. Engl. J. Med., January 1, 2004; 350(1): 48 - 58. [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Rakic, V. Lambert, L. Devy, A. Luttun, P. Carmeliet, C. Claes, L. Nguyen, J.-M. Foidart, A. Noel, and C. Munaut Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3186 - 3193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oshima, C. Shukunami, J. Honda, K. Nishida, F. Tashiro, J.-i. Miyazaki, Y. Hiraki, and Y. Tano Expression and Localization of Tenomodulin, a Transmembrane Type Chondromodulin-I-Related Angiogenesis Inhibitor, in Mouse Eyes Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 1814 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ishida, T. Usui, K. Yamashiro, Y. Kaji, E. Ahmed, K. G. Carrasquillo, S. Amano, T. Hida, Y. Oguchi, and A. P. Adamis VEGF164 Is Proinflammatory in the Diabetic Retina Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2155 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Rakoczy, M. Brankov, A. Fonceca, T. Zaknich, B. C. Rae, and C.-M. Lai Enhanced Recombinant Adeno-Associated Virus-Mediated Vascular Endothelial Growth Factor Expression in the Adult Mouse Retina: A Potential Model for Diabetic Retinopathy Diabetes, March 1, 2003; 52(3): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yoshida, A. Yoshida, T. Ishibashi, S. G. Elner, and V. M. Elner Role of MCP-1 and MIP-1{alpha} in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization J. Leukoc. Biol., January 1, 2003; 73(1): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Witmer, H. G. Blaauwgeers, H. A. Weich, K. Alitalo, G. F. J. M. Vrensen, and R. O. Schlingemann Altered Expression Patterns of VEGF Receptors in Human Diabetic Retina and in Experimental VEGF-Induced Retinopathy in Monkey Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 849 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Qaum, Q. Xu, A. M. Joussen, M. W. Clemens, W. Qin, K. Miyamoto, H. Hassessian, S. J. Wiegand, J. Rudge, G. D. Yancopoulos, et al. VEGF-initiated Blood-Retinal Barrier Breakdown in Early Diabetes Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2408 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schwesinger, C. Yee, R. M. Rohan, A. M. Joussen, A. Fernandez, T. N. Meyer, V. Poulaki, J. J. K. Ma, T. M. Redmond, S. Liu, et al. Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium Am. J. Pathol., March 1, 2001; 158(3): 1161 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baffi, G. Byrnes, C.-C. Chan, and K. G. Csaky Choroidal Neovascularization in the Rat Induced by Adenovirus Mediated Expression of Vascular Endothelial Growth Factor Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3582 - 3589. [Abstract] [Full Text]
|
|
|
|
|
|
W. W. Hauswirth and L. Beaufrere Ocular Gene Therapy: Quo Vadis? Invest. Ophthalmol. Vis. Sci., September 1, 2000; 41(10): 2821 - 2826. [Full Text]
|
|
|
|
|
|
S. Hoffmann, R. Masood, Y. Zhang, S. He, S. J. Ryan, P. Gill, and D. R. Hinton Selective Killing of RPE with a Vascular Endothelial Growth Factor Chimeric Toxin Invest. Ophthalmol. Vis. Sci., July 1, 2000; 41(8): 2389 - 2393. [Abstract] [Full Text]
|
|
|
|
|
|
T. G Sheidow, P. L Hooper, C. Crukley, J. Young, and J G. Heathcote Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis Br. J. Ophthalmol., July 1, 2000; 84(7): 750 - 756. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
